Cantor Fitzgerald Sticks to Its Buy Rating for X4 Pharmaceuticals (XFOR)
Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on X4 Pharmaceuticals (XFOR – Research Report) on January 14 and set a price ...
Cantor Fitzgerald Sticks to Its Buy Rating for PTC Therapeutics (PTCT)
In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on PTC Therapeutics (PTCT – Research Report), ...
Hosted on MSN2d
Cantor Fitzgerald Initiates Coverage of Onto Innovation (ONTO) with Overweight Recommendation
Fintel reports that on January 13, 2025, Cantor Fitzgerald initiated coverage of Onto Innovation (NYSE:ONTO) with a ...
Intra-Cellular Therapies (NASDAQ:ITCI) Upgraded to “Strong-Buy” at Cantor Fitzgerald
Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) was upgraded by equities research analysts at Cantor Fitzgerald from ...
Cantor Fitzgerald Initiates Coverage on Varonis Systems, Inc. (VRNS) with Overweight Rating: AI and Cybersecurity Drive Growth Outlook
We recently compiled a list of the 13 AI News and Ratings on Wall Street’s Radar. In this article, we are going to take a ...
Cantor Fitzgerald Raises Amazon.com, Inc. (AMZN)’s Price Target to $270, Highlighting Strong AI Growth and Future Potential
We recently compiled a list of the 14 AI Stocks Making Waves on Wall Street. In this article, we are going to take a look at ...
Cantor Fitzgerald Predicts Weaker Earnings for Maplebear
Stock analysts at Cantor Fitzgerald dropped their FY2024 earnings per share estimates for Maplebear in a research note issued on Tuesday, January 7th. Cantor Fitzgerald analyst D. Mathivanan now ...
Cantor Fitzgerald, L.P.: Cantor Equity Partners I, Inc. Announces Pricing of $200 Million Initial Public Offering
Cantor Equity Partners I, Inc. (Nasdaq: CEPO) (the "Company") announced today that it priced its initial public offering ...
Investing3d
Cantor Fitzgerald sets overweight rating for Onto Innovation stock on outlook
Monday - Cantor Fitzgerald has initiated coverage on Onto Innovation Inc. (NYSE: NYSE:ONTO) shares with an Overweight rating and has set a price target of $250. The new rating is based on the firm ...
Nasdaq24d
Cantor Fitzgerald Initiates Coverage of Voyager Therapeutics (VYGR) with Overweight Recommendation
Fintel reports that on January 10, 2025, Cantor Fitzgerald initiated coverage of Voyager Therapeutics (NasdaqGS:VYGR) with a Overweight recommendation. As of December 23, 2024, the average one ...